Melbourne spin-out Hatchtech receives AU$12.6m for head lice treatment.
Australia-based pharmaceutical company Hatchtech, a spin-out of the University of Melbourne, has received AU$12.6m ($11.9m) for a new head lice-killing product.
The latest round was led by venture firm OneVentures, which was joined in participation by University of Melbourne, the Queensland Biotechnology Fund and spin-out focused venture fund Uniseed, and brings the company’s total venture capital and grant investments to $35.6m. The firm’s shareholders include OneVentures, Bowles, GBS Venture Partners, the University of Melbourne Endowment Trust, Queensland Biotechnology Funds, Uniseed,…
